Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

nticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commissi
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014  CytoSorbents Corporation (OTCQB: ... European Union approved CytoSorb® cytokine adsorber to treat ... the Beacon of Light Award at last night,s ... Dr. Phillip Chan , Chief ... honor to be recognized by the New Jersey ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
(Date:11/21/2014)... 2014  Alere Inc. (NYSE: ALR ), ... Juliet Cunningham as Vice President, Investor Relations. ... for driving communications with the investment community. ... changes to increase shareholder value, it is critical that ... Nawana, Chief Executive Officer. "We are delighted that ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... Biomedical, Inc., a privately held company that has developed an ... announced today it has reached an agreement with The ... Services, Inc. , to be the premier manufacturer of the ... seven year contract also includes development and engineering services from ...
... Incorporated (NYSE: DGX ), the world,s leading ... the successful completion of its previously announced agreement with ... the terms of the transaction, Quest Diagnostics has acquired ... in-patient labs for the four Lovelace hospitals, as well ...
Cached Medicine Technology:Pepex Biomedical Signs Seven Year Deal to Manufacture "Trio™" 2Pepex Biomedical Signs Seven Year Deal to Manufacture "Trio™" 3Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories 2
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... CHICAGO (PRWEB) November 24, 2014 ... VolparaAnalytics version 1.2 at the 100th Annual Meeting ... November 30-December 5, 2014 (RSNA Booth 1752 – ... version of VolparaAnalytics and the rest of its ... VolparaDensity and VolparaDoseRT, which enable personalized measurements of ...
(Date:11/24/2014)... Virginia (PRWEB) November 24, 2014 Residents ... center stage in this year’s SENIORS GOT TALENT, an ... Guide. , From piano players to classic crooners, to ... clear that older adults are indeed living young. , ... competition because there’s a cash prize, has always been ...
(Date:11/24/2014)... Olaparib functions as a chemical of ... one of the first PARP inhibitors. Sufferers with BRCA1/2 ... of melanoma, and are often immune to other types ... malignancies a exclusive weaknesses, as the tissues of melanoma ... and allow them to proceed splitting. This implies that ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
... the latest study by the Mayo clinic, injecting an anesthetic ... ,The new study that is being presented today ... the American Urological Association, in San Diego, had found that ... of pain during their biopsy. It was explained that the ...
... disease of the rich and comfortably off in India has now ... classes in India.// , The disease has become so ... with the diabetic population in the country reaching a count of ... to more than double. ,International attention has been drawn ...
... caused drastic increase in cancer among kids across Europe. They ... cases of cancer in kids identified between 1978 and 1997 ... to the results, there was an increase by an average ... in children under the age of 14. ,Majority ...
... According to a review that was published in the Friday’s issue ... reduce their risk of fractures in the later years.// ... got by the age of 18 years. Hence, it is expected ... effects of age-related bone loss and osteoporosis. ,The results ...
... used to treat migraine headaches can be effective in ... zolmitriptan targets nerves that carry pain signals, Dr. Peter ... said.// ,Cluster headaches are not as common as ... 92 patients with cluster headaches. In the final analysis ...
... wells near the Queen’s Balmoral Castle in Scotland kills cancer ... biochemistry at the University of Maribor in Slovenia said that ... and compared them to those placed in normal lab water. ... of colon cancer cells 62.5 percent more quickly than normal ...
Cached Medicine News:Health News:India’s Silent Killer on the Prow 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
Inquire...
Inquire...
Medicine Products: